|
March 2024 LEFLUNOMIDE: AN OVERLOOKED DRUG FOR YOUR TREATMENT TOOLKIT?Featuring: Eric M. Ruderman, MD
Eric M. Ruderman, MD, professor of Rheumatology at Northwestern Medicine, attended the 2024 Rheumatology Winter Clinical Symposium, where he presented clinical trial data that was published after the FDA approval of leflunomide as a rheumatoid arthritis (RA) treatment. Despite being overshadowed by the introduction of biologics, clinical trial data suggests that leflunomide still has a role in the treatment of RA. It has shown similar efficacy to methotrexate and sulfasalazine in improving RA symptoms, and it has been found to be comparable to a biologic. Leflunomide may also have a cost benefit in developing countries where biologics are not as accessible. Additionally, the drug has shown efficacy in the treatment of psoriatic arthritis, and it has been considered as an adjunct therapy for patients who experience joint symptoms despite improvement in skin disease with biologics. Read the full article on Medscape. |
Eric M. Ruderman, MD, Professor of Rheumatology at Northwestern Medicine
Refer a PatientNorthwestern Medicine welcomes the opportunity to partner with you in caring for your patients.
|
You May Also Like
|
|
|